RATIO-LISINOPRIL Z TABLET

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

LISINOPRIL

可用日期:

RATIOPHARM INC DIVISION OF TEVA CANADA LIMITED

ATC代码:

C09AA03

INN（国际名称）:

LISINOPRIL

剂量:

5MG

药物剂型:

TABLET

组成:

LISINOPRIL 5MG

给药途径:

ORAL

每包单位数:

100/500

处方类型:

Prescription

治疗领域:

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

產品總結:

Active ingredient group (AIG) number: 0121550003; AHFS:

授权状态:

CANCELLED POST MARKET

授权日期:

2014-09-19

产品特点

_ _
_ratio-LISINOPRIL Z 5 mg, 10 mg and 20 mg Tablets _
_Page 1 of 39 _
PRODUCT MONOGRAPH
RATIO-LISINOPRIL Z
Lisinopril
Tablets 5 mg, 10 mg and 20 mg
USP
Angiotensin Converting Enzyme Inhibitor
ratiopharm inc.
Canada J7J 1P3
DATE OF PREPARATION: SEPTEMBER 20, 2007
CONTROL NUMBER: 110419
_ _
_ratio-LISINOPRIL Z 5 mg, 10 mg and 20 mg Tablets _
_Page 2 of 39 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION........................................................ 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL
USE.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
4
WARNINGS AND PRECAUTIONS
……………………………………………………..4
ADVERSE
REACTIONS.................................................................................................
10
DRUG INTERACTIONS
.................................................................................................
15
DOSAGE AND
ADMINISTRATION.............................................................................
16
SYMPTOMS AND TREATMENT OF OVERDOSAGE
............................................... 19
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 19
STORAGE AND
STABILITY.........................................................................................
22
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 22
PART II: SCIENTIFIC INFORMATION
..............................................................................
23
PHARMACEUTICAL
INFORMATION.........................................................................
23
CLINICAL
TRIALS.........................................................................................................
24
DETAILED
PHARMACOLOGY...............................................................